Lyell Immunopharma, Inc. (LYEL) Stock Grade

About Lyell Immunopharma, Inc.'s fundamentals

Lyell Immunopharma is a biotechnology company with a market capitalization of $526.1 million that reported a significant net loss in its latest annual statement, resulting in a net margin of -762355.6%. The company experienced a steep revenue decline of 41.0% year-over-year, indicating shrinking sales relative to the prior period. As a pre-profit or early-stage biotech company, standard profitability metrics like P/E ratio and return on equity are not applicable, and the company does not pay a dividend.